ATC Group: C01EA01 Alprostadil

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01EA01 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01E Other cardiac preparations
4 C01EA Prostaglandins
5 C01EA01 Alprostadil

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 0.5 mg

Active ingredients in C01EA01

Active Ingredient Description
Alprostadil

Alprostadil is chemically identical to prostaglandin E1, the actions of which include vasodilatation of blood vessels in the erectile tissues of the corpora cavernosa and increase in cavernosal artery blood flow, causing penile rigidity.

Related product monographs

Title Information Source Document Type  
PROSTIN VR Concentrate for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Brazil (BR)

Canada (CA)

Croatia (HR)

Ecuador (EC)

Finland (FI)

France (FR)

Hong Kong (HK)

Israel (IL)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Singapore (SG)

South Africa (ZA)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.